(R)-Lansoprazole


Catalog No. Size PriceQuantity
M9131-2 Solid 2 mg $80
M9131-10 Solid 10 mg $240

Description

Dexlansoprazole, also known as Dexilant and TAK-390MR, is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosivegastroesophageal reflux disease.

Product information

CAS Number: 138530-94-6

Molecular Weight: 369.36

Formula: C16H14F3N3O2S

Synonym:

Dexlansoprazole

Kapidex

Dexilant

Chemical Name: 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole

Smiles: CC1=C(C=CN=C1C[S@@](=O)C1NC2=CC=CC=C2N=1)OCC(F)(F)F

InChiKey: MJIHNNLFOKEZEW-RUZDIDTESA-N

InChi: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (270.74 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

The plasma concentrations of (R)-lansoprazole are remarkably higher in all three CYP2C19 genotype groups than those of the corresponding (S)-enantiomer. The AUC0-∞ Cmax and elimination half-life of (R)-lansoprazole are significantly greater and longer, respectively, than those of the (S)-enantiomer for all three genotype groups.

References:

  1. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.
  2. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.
  3. M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed